MSD-Moderna Phase III readout backs personalised mRNA neoantigen combination adjuvant therapy for melanoma

First combination regimen to demonstrate significant reduction in recurrence risk in completely resected stage IIB-IV melanoma compared to Keytruda alone as adjuvant treatment.